The public health authorities in Spain have issued an alert concerning cholesterol pills to bring down LDL levels.

The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), has ordered the withdrawal of a batch of Rosuvastatina Cinfa 20mg 28 pills/capsules, batch nº BT2109 with a use by date of 31/01/2025, and batch nº BT2286, with a use by date of 31/01/2025.

The reason being that they have discovered impurities within their contents. However, they have pointed out that this defect does not mean that there is a serious danger to the health of a patient. You might grow another head under your armpit, but nothing serious – just joking!

Rosuvastatina is prescribed to people with a high level of LDL (Low Density Lipoprotein) which accumulates in arteries causing vascular obstructions.

This week, the AEMPS has also ordered the withdrawal of a thyroid drug, Solsint produced by IBSA, for the same reason. The details are as follows:

* Solsint, 25mg, 30 doses (NR: 85617, CN: 729906) Batch/Nº: 220657, use by 31/12/2023.
* Solsint, 50mg, 30 doses (NR: 85618, CN: 729908) Batch/Nº: 220752, use by 31/01/2024.
* Solsint, 100mg, 30 doses (NR: 85609, CN: 729889) Batch/Nº: 220658, use by 31/12/2023.
* Solsint, 125mg, 30 doses (NR: 85611, CN: 729893) Batch/Nº: 220753, use by 31/01/2024.
* Solsint, 137mg, 30 doses (NR: 85612, CN: 729895) Batch/Nº: 220755, use by 31/01/2024.
* Solsint, 175mg, 30 doses (NR: 85615, CN: 729901) Batch/Nº: 220662, use by 31/12/2023.

(News: Spain)